STOCK TITAN

Director at Precigen (NASDAQ: PGEN) receives stock, RSUs and options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PRECIGEN, INC. director Frank Steven reported equity compensation grants consisting of common shares, restricted stock units, and stock options. He received 14,245 shares of common stock at $3.51 per share, issued in lieu of a $50,000 annual cash retainer, bringing his direct common stock holdings to 1,154,552 shares.

He was also granted 35,612 restricted stock units, each representing one share of common stock and vesting in full on March 10, 2027, plus options to purchase 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. These transactions are compensation-related awards rather than open‑market trading.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Frank Steven

(Last) (First) (Middle)
20374 SENECA MEADOWS PARKWAY

(Street)
GERMANTOWN MD 20876

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/10/2026 A 14,245 A $3.51(1) 1,154,552 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 03/10/2026 A 35,612 (3) (3) Common Stock 35,612 $0 35,612 D
Option to Purchase Common Stock (Right to Buy) $3.51 03/10/2026 A 41,073 03/10/2026 03/10/2036 Common Stock 41,073 $0 41,073 D
Explanation of Responses:
1. The shares were issued to the reporting person in lieu of an annual retainer of $50,000.
2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
3. The RSUs vest in full on March 10, 2027.
/s/ Steven Frank, by Donald P. Lehr, as attorney-in-fact 03/12/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Precigen (PGEN) director Frank Steven report?

Director Frank Steven reported receiving common shares, restricted stock units, and stock options as equity compensation. The grants include 14,245 common shares, 35,612 RSUs, and options for 41,073 shares, all awarded on March 10, 2026 as non‑market transactions.

How many Precigen (PGEN) common shares does Frank Steven hold after this Form 4?

After the reported transactions, Frank Steven directly holds 1,154,552 shares of Precigen common stock. This total reflects the addition of 14,245 new common shares granted as part of his director compensation on March 10, 2026, as disclosed in the filing.

What are the key terms of the Precigen (PGEN) stock options granted to Frank Steven?

Frank Steven received options to purchase 41,073 shares of Precigen common stock at an exercise price of $3.51 per share. These options were granted on March 10, 2026 and are scheduled to expire on March 10, 2036, giving a long‑dated incentive.

When do Frank Steven’s Precigen (PGEN) restricted stock units vest?

Frank Steven’s 35,612 restricted stock units vest in full on March 10, 2027. Each RSU represents a contingent right to receive one share of Precigen common stock, aligning his compensation with future company performance beyond the grant date.

Why did Precigen (PGEN) issue common shares to Frank Steven at $3.51?

The 14,245 common shares at $3.51 were issued to Frank Steven in lieu of a $50,000 annual cash retainer. This converts his director fee into equity, increasing his ownership stake and more closely tying his compensation to Precigen’s share performance.
Precigen Inc

NASDAQ:PGEN

View PGEN Stock Overview

PGEN Rankings

PGEN Latest News

PGEN Latest SEC Filings

PGEN Stock Data

1.24B
305.62M
Biotechnology
Pharmaceutical Preparations
Link
United States
GERMANTOWN